Kevzara Purple Book BLA 761037

BLA number
761037
Proprietary names
Kevzara
Proper names
sarilumab
Applicant
Sanofi-Aventis U.S. LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001Kevzarasarilumab351(a)150MG/1.14MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2017-05-22
002Kevzarasarilumab351(a)200MG/1.14MLInjectionSubcutaneousPre-Filled SyringeRxLicensed2017-05-22
003Kevzarasarilumab351(a)150MG/1.14MLInjectionSubcutaneousAutoinjectorRxLicensed2018-04-13
004Kevzarasarilumab351(a)200MG/1.14MLInjectionSubcutaneousAutoinjectorRxLicensed2018-04-13

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-05-01U001Kevzara351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U002Kevzara351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U003Kevzara351(a)RxSanofi-Aventis U.S. LLC
2021-05-01U004Kevzara351(a)RxSanofi-Aventis U.S. LLC
2020-05-01R001Kevzara351(a)Rxsanofi-aventis U.S. LLC
2020-05-01R002Kevzara351(a)Rxsanofi-aventis U.S. LLC
2020-05-01R003Kevzara351(a)Rxsanofi-aventis U.S. LLC
2020-05-01R004Kevzara351(a)Rxsanofi-aventis U.S. LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Kevzara351(a)RxLicensed2017-05-22
2020-05-01002Kevzara351(a)RxLicensed2017-05-22
2020-05-01003Kevzara351(a)RxLicensed2018-04-13
2020-05-01004Kevzara351(a)RxLicensed2018-04-13